- Home
- TRIP vs MLTX Comparison
TRIP vs MLTX Comparison
Compare TRIP & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | MLTX |
|---|---|---|
| Founded | 2000 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRIP | MLTX |
|---|---|---|
| Price | $10.72 | $16.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $14.58 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 3.7M | 1.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,556,000,000.00 | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | $34.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.01 | $5.95 |
| 52 Week High | $20.16 | $62.75 |
Technical Indicators
Market Signals| Indicator | TRIP | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 48.24 |
| Support Level | $9.36 | $16.52 |
| Resistance Level | $11.08 | $19.03 |
| Average True Range (ATR) | 0.51 | 1.01 |
| MACD | 0.23 | -0.04 |
| Stochastic Oscillator | 93.65 | 34.37 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform (33% of 2024 sales). Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.